Clinkenbeard, Erica L.
White, Kenneth E.
Funding for this research was provided by:
National Institutes of Health (R01-DK063934)
National Institutes of Health (R01-DK95784 (KEW))
National Institutes of Health (F32-AR065389 (ELC))
Article History
First Online: 3 February 2016
Compliance with Ethical Standards
:
: Erica L. Clinkenbeard declares no conflict of interest.Kenneth E. White received royalties from Kyowa Hakko Kirin Co., Ltd. for licensing of the FGF23 gene and the anti-FGF23 monoclonal antibody trials, as well as research funding from Eli Lilly.
: With regard to the authors’ research cited in this paper, all institutional and national guidelines for the care and use of laboratory animals were followed. Additionally, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Free to read: This content has been made available to all.